Assenagon Asset Management S.A. Raises Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Assenagon Asset Management S.A. grew its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 67.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 311,617 shares of the specialty pharmaceutical company's stock after buying an additional 125,438 shares during the quarter. Assenagon Asset Management S.A. owned 1.48% of ANI Pharmaceuticals worth $17,226,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. State Street Corp increased its stake in ANI Pharmaceuticals by 9.1% in the 3rd quarter. State Street Corp now owns 703,843 shares of the specialty pharmaceutical company's stock worth $41,991,000 after purchasing an additional 58,698 shares during the period. Dimensional Fund Advisors LP increased its holdings in ANI Pharmaceuticals by 3.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 630,226 shares of the specialty pharmaceutical company's stock valued at $40,132,000 after purchasing an additional 21,053 shares during the period. Pacer Advisors Inc. raised its position in ANI Pharmaceuticals by 23,259.8% during the 3rd quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company's stock valued at $33,907,000 after purchasing an additional 565,910 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in ANI Pharmaceuticals by 159.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company's stock worth $33,101,000 after buying an additional 340,854 shares during the period. Finally, Global Alpha Capital Management Ltd. grew its position in shares of ANI Pharmaceuticals by 1.8% in the 3rd quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company's stock worth $32,005,000 after buying an additional 9,500 shares during the last quarter. Institutional investors own 76.05% of the company's stock.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 7,500 shares of ANI Pharmaceuticals stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total value of $418,425.00. Following the transaction, the chief financial officer now owns 154,468 shares in the company, valued at $8,617,769.72. The trade was a 4.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Nikhil Lalwani sold 33,481 shares of the stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total value of $1,941,563.19. Following the sale, the chief executive officer now owns 370,378 shares of the company's stock, valued at approximately $21,478,220.22. This represents a 8.29 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,381 shares of company stock valued at $2,441,556 in the last quarter. 12.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ANIP. Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a "strong-buy" rating in a research note on Wednesday, December 11th. HC Wainwright reiterated a "buy" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Leerink Partners began coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an "outperform" rating and a $80.00 price objective for the company. Piper Sandler initiated coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They issued an "overweight" rating and a $68.00 target price on the stock. Finally, Truist Financial raised their price target on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a "hold" rating in a report on Tuesday, October 22nd. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $77.71.

ANI Pharmaceuticals Trading Up 1.7 %

NASDAQ ANIP traded up $0.96 on Friday, hitting $58.46. 302,520 shares of the stock were exchanged, compared to its average volume of 215,598. ANI Pharmaceuticals, Inc. has a 52-week low of $52.50 and a 52-week high of $70.81. The firm has a market capitalization of $1.23 billion, a P/E ratio of -106.29 and a beta of 0.73. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The stock has a fifty day moving average price of $56.36 and a two-hundred day moving average price of $58.84.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, topping analysts' consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The company had revenue of $148.30 million for the quarter, compared to analyst estimates of $144.37 million. During the same period in the prior year, the company posted $1.05 EPS. The firm's revenue for the quarter was up 12.5% on a year-over-year basis. Research analysts forecast that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current fiscal year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.